{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:22:55Z","timestamp":1790122975117,"version":"4.0.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background\/Objectives<\/jats:title>\n                    <jats:p>To assess geographically global clinical practice guidelines (CPGs) for neovascular age-related macular degeneration (nAMD) management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic literature review (SLR) of CPGs for nAMD management was conducted using Embase and MEDLINE databases, Guideline Central, Health Technology Assessment bodies, professional ophthalmology associations, and backwards citation tracking. CPGs published between January 2010\u2013October 2023 were included and independently assessed by four reviewers using the Appraisal of Guidelines for Research and Evaluation II (AGREE II). CPGs were qualitatively assessed for anatomical measurements (optical coherence tomography [OCT] and visual acuity [VA]). PROSPERO identification is CRD42023473223.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Nine of 147 identified global CPGs were included in the SLR for diagnosis, treatment, and disease monitoring for nAMD. Overall AGREE II scores were 62\u201395 (mean [standard deviation] score 75 [10.6]). Strongest domains were Scope and Purpose (86.6 [11.0]), Clarity of Presentation (84.3 [13.0]), and Editorial Independence (89.1 [15.4]); Stakeholder Involvement (63.4 [16.6]), Applicability (73.0 [12.6]), and Rigor of Development (55.4 [25.9]) were lowest. 4\/9 CPGs were \u201cRecommended\u201d by reviewers, and 5\/9 were \u201cRecommended with Modifications\u201d. All CPGs recommended OCT for initial diagnosis. 2\/9 CPGs did not mention VA. For managing pharmacological interventions, 4\/9 CPGs recommended using VA, and three recommended OCT. Eight CPGs recommended using either VA or OCT for disease monitoring while on anti-vascular endothelial growth factor (VEGF) treatment. 6\/9 CPGs recommended screening for VA and 7\/9 CPGs recommended using OCT to change anti-VEGF intervals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CPG methods, recommendations on applicability in resource-constrained systems, and patient advocacy\/perspectives will improve CPG trustworthiness and transparency.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41433-025-03829-8","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T06:33:11Z","timestamp":1747290791000},"page":"2223-2230","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Systematic review of clinical practice guidelines for the management of neovascular age-related macular degeneration"],"prefix":"10.1038","volume":"39","author":[{"given":"Jennifer I.","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"McAllister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Faux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Komal","family":"Bawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Mearns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shriji","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4423-582X","authenticated-orcid":false,"given":"Galin","family":"Spicer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3476-7019","authenticated-orcid":false,"given":"Amanda","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7657-0809","authenticated-orcid":false,"given":"David","family":"Tabano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"issue":"1","key":"3829_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41572-021-00265-2","volume":"7","author":"M Fleckenstein","year":"2021","unstructured":"Fleckenstein M, Keenan TDL, Guymer RH, Chakravarthy U, Schmitz-Valckenberg S, Klaver CC, et al. Age-related macular degeneration. Nat Rev Dis Prim. 2021;7(1):31.","journal-title":"Nat Rev Dis Prim."},{"issue":"2","key":"3829_CR2","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X, Cheung CMG, Klein R, Cheng CY, et al. Global prevalence of agerelated macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106\u2013e116.","journal-title":"Lancet Glob Health"},{"issue":"5","key":"3829_CR3","first-page":"e39624","volume":"15","author":"M Chaudhuri","year":"2023","unstructured":"Chaudhuri M, Hassan Y, Bakka Vemana PPS, Bellary Pattanashetty MS, Abdin ZU, Siddiqui HF. Age-related macular degeneration: an exponentially emerging imminent threat of visual impairment and irreversible blindness. Cureus. 2023;15(5):e39624.","journal-title":"Cureus."},{"issue":"1","key":"3829_CR4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.neuron.2012.06.018","volume":"75","author":"J Ambati","year":"2012","unstructured":"Ambati J, Fowler BJ. Mechanisms of age-related macular degeneration. Neuron. 2012;75(1):26\u201339.","journal-title":"Neuron."},{"issue":"1","key":"3829_CR5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.oret.2018.08.002","volume":"3","author":"R Parikh","year":"2019","unstructured":"Parikh R, Pirakitikulr N, Chhablani J, Sakurada Y, Singh RP, Modi YS. A multinational comparison of anti\u2013vascular endothelial growth factor use: the United States, the United Kingdom, and Asia-Pacific. Ophthalmol Retin. 2019;3(1):16\u201326.","journal-title":"Ophthalmol Retin"},{"issue":"1","key":"3829_CR6","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1093\/intqhc\/mzv115","volume":"28","author":"T Kredo","year":"2016","unstructured":"Kredo T, Bernhardsson S, Machingaidze S, Young T, Louw Q, Ochodo E, et al. Guide to clinical practice guidelines: the current state of play. Int J Qual Health Care. 2016;28(1):122\u20138.","journal-title":"Int J Qual Health Care"},{"key":"3829_CR7","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/j.injury.2022.01.047","volume":"54","author":"E Guerra-Farfan","year":"2023","unstructured":"Guerra-Farfan E, Garcia-Sanchez Y, Jornet-Gibert M, Nunez JH, Balaguer-Castro M, Madden K. Clinical practice guidelines: the good, the bad, and the ugly. Injury. 2023;54:S26\u2013S29.","journal-title":"Injury."},{"issue":"12","key":"3829_CR8","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.jclinepi.2010.06.005","volume":"63","author":"AL Dans","year":"2010","unstructured":"Dans AL, Dans LF. Appraising a tool for guideline appraisal (the AGREE II instrument). J Clin Epidemiol. 2010;63(12):1281\u20132.","journal-title":"J Clin Epidemiol"},{"key":"3829_CR9","doi-asserted-by":"publisher","first-page":"i1152","DOI":"10.1136\/bmj.i1152","volume":"352","author":"MC Brouwers","year":"2016","unstructured":"Brouwers MC, Kerkvliet K, Spithoff K. AGREE Next Steps Consortium. The AGREE Reporting Checklist: a tool to improve reporting of clinical practice guidelines. BMJ. 2016;352:i1152.","journal-title":"BMJ."},{"issue":"18","key":"3829_CR10","doi-asserted-by":"publisher","first-page":"E839","DOI":"10.1503\/cmaj.090449","volume":"182","author":"MC Brouwers","year":"2010","unstructured":"Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ. 2010;182(18):E839\u2013842.","journal-title":"CMAJ."},{"issue":"29-30","key":"3829_CR11","first-page":"513","volume":"117","author":"A Stahl","year":"2020","unstructured":"Stahl A. The diagnosis and treatment of age-related macular degeneration. Dtsch Arztebl Int. 2020;117(29-30):513\u201320.","journal-title":"Dtsch Arztebl Int"},{"issue":"12","key":"3829_CR12","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1038\/s41433-022-02360-4","volume":"37","author":"RLW Hanson","year":"2023","unstructured":"Hanson RLW, Airody A, Sivaprasad S, Gale RP. Optical coherence tomography imaging biomarkers associated with neovascular age-related macular degeneration: a systematic review. Eye (Lond). 2023;37(12):2438\u201353.","journal-title":"Eye (Lond)"},{"key":"3829_CR13","doi-asserted-by":"publisher","first-page":"9994098","DOI":"10.1155\/2021\/9994098","volume":"2021","author":"C Metrangolo","year":"2021","unstructured":"Metrangolo C, Donati S, Mazzola M, Fontanel L, Messina W, D'alterio G, et al. OCT biomarkers in neovascular age-related macular degeneration: a narrative review. J Ophthalmol. 2021;2021:9994098.","journal-title":"J Ophthalmol"},{"issue":"12","key":"3829_CR14","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537\u201348.","journal-title":"Ophthalmology."},{"issue":"1","key":"3829_CR15","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","volume":"116","author":"DM Brown","year":"2009","unstructured":"Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116(1):57\u201365.e5.","journal-title":"Ophthalmology."},{"issue":"14","key":"3829_CR16","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419\u201331.","journal-title":"N Engl J Med"},{"issue":"12","key":"3829_CR17","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1038\/s41433-020-0799-y","volume":"34","author":"U Chakravarthy","year":"2020","unstructured":"Chakravarthy U, Pillai N, Syntosi A, Barclay L, Best C, Sagkriotis A. Association between visual acuity, lesion activity markers and retreatment decisions in neovascular age-related macular degeneration. Eye (Lond). 2020;34(12):2249\u201356.","journal-title":"Eye (Lond)"},{"issue":"7","key":"3829_CR18","first-page":"4902","volume":"65","author":"B Bhatia","year":"2024","unstructured":"Bhatia B, Sim SY, Chalkiadaki E, Koutsocheras G, Nicholson L, Selvam S, et al. Impact of Disease Activity Criteria on Extending Injection Intervals in Real-World Patients with Neovascular Age-related Macular Degeneration: A Moorfields Analysis. Invest Ophthalmol Vis Sci. 2024;65(7):4902\u201388.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"14","key":"3829_CR19","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1038\/s41433-024-03110-4","volume":"38","author":"S Thottarath","year":"2024","unstructured":"Thottarath S, Gurudas S, Chandak S, Patel PJ, Kotagiri A, Pearce I, et al. Impact of treat and extend criteria on proportions that can be extended after loading phase of 2 mg aflibercept therapy for neovascular age related macular degeneration: PRECISE Report 5. Eye (Lond). 2024;38(14):2737\u201343.","journal-title":"Eye (Lond)"},{"issue":"3","key":"3829_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta2030","volume":"2","author":"MK Murphy","year":"1998","unstructured":"Murphy MK, Black NA, Lamping DL, McKee CM, Sanderson CF, Ashkam J, et al. Consensus development methods, and their use in clinical guideline development. Health Technol Assess. 1998;2(3):1\u201388. i\u2013iv","journal-title":"Health Technol Assess"},{"key":"3829_CR21","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ."},{"issue":"6","key":"3829_CR22","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1097\/APO.0000000000000445","volume":"10","author":"V Chaikitmongkol","year":"2021","unstructured":"Chaikitmongkol V, Sagong M, Lai TYY, Tan GSW, Ngah NF, Ohji M, et al. Treatand- extend regimens for the management of neovascular age-related macular degeneration and polypoidal choroidal vasculopathy: consensus and recommendations from the Asia-Pacific Vitreo-retina Society. Asia Pac. J Ophthalmol (Phila). 2021;10(6):507\u201318.","journal-title":"J Ophthalmol (Phila)"},{"issue":"12","key":"3829_CR23","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1016\/j.jfma.2021.06.012","volume":"120","author":"L Yeung","year":"2021","unstructured":"Yeung L, Hsieh YT, Yang CH, Chen LJ, Chen SJ, Cheng CK, et al. Management of neovascular age-related macular degeneration: Taiwan expert consensus. J Formos Med Assoc. 2021;120(12):2061\u201371.","journal-title":"J Formos Med Assoc"},{"issue":"A105 Suppl","key":"3829_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/aos.13501","volume":"95","author":"R Tuuminen","year":"2017","unstructured":"Tuuminen R, Uusitalo-Jarvinen H, Aaltonen V, Hautala N, Kaipiainen S, Laitamaki N, et al. The Finnish national guideline for diagnosis, treatment and follow-up of patients with wet age-related macular degeneration. Acta Ophthalmol. 2017;95(A105 Suppl):1\u20139.","journal-title":"Acta Ophthalmol."},{"key":"3829_CR25","unstructured":"National Institute for Health and Care Excellence (NICE). Age-related macular degeneration. NICE guideline [NG82]. 2018. https:\/\/www.nice.org.uk\/guidance\/ng82"},{"issue":"1","key":"3829_CR26","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1016\/j.ophtha.2019.09.024","volume":"127","author":"CJ Flaxel","year":"2020","unstructured":"Flaxel CJ, Adelman RA, Bailey ST, Fawzi A, Lim JI, Vemulakondaet GA, et al. Age-related macular degeneration Preferred Practice Pattern\u00ae. Ophthalmology. 2020;127(1):P1\u201365.","journal-title":"Ophthalmology."},{"issue":"1","key":"3829_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12886-021-02231-8","volume":"22","author":"CK Cheng","year":"2022","unstructured":"Cheng CK, Chen SJ, Chen JT, Chen LJ, Chen SN, Chen WL, et al. Optimal approaches and criteria to treat-and-extend regimen implementation for neovascular age-related macular degeneration: experts consensus in Taiwan. BMC Ophthalmol. 2022;22(1):25\u2013726.","journal-title":"BMC Ophthalmol"},{"issue":"9","key":"3829_CR28","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1136\/bjophthalmol-2014-305702","volume":"98","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Chong V, Loewenstein A, Larsen M, Souied E, Schlingermann R, et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol. 2014;98(9):1144\u201367.","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"3829_CR29","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s12325-016-0332-7","volume":"33","author":"S Androudi","year":"2016","unstructured":"Androudi S, Dastiridou A, Pharmakakis N, Stefaniotou M, Kalogeropoulos, Symeonidis C, et al. Guidelines for the management of wet age-related macular degeneration: recommendations from a panel of Greek experts. Adv Ther. 2016;33(5):715\u201326.","journal-title":"Adv Ther"},{"issue":"3","key":"3829_CR30","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.jcjo.2012.03.007","volume":"47","author":"AF Cruess","year":"2012","unstructured":"Cruess AF, Berger A, Colleaux K, Greve M, Harvey P, Kerteset PJ, et al. Canadian expert consensus: optimal treatment of neovascular age-related macular degeneration. Can J Ophthalmol. 2012;47(3):227\u201335.","journal-title":"Can J Ophthalmol"},{"issue":"3","key":"3829_CR31","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/eye.2011.335","volume":"26","author":"KN Amissah-Arthur","year":"2012","unstructured":"Amissah-Arthur KN, Panneerselvam S, Narendran N, Yang YC. Optical coherence tomography changes before the development of choroidal neovascularization in second eyes of patients with bilateral wet macular degeneration. Eye (Lond). 2012;26(3):394\u20139.","journal-title":"Eye (Lond)"},{"issue":"4","key":"3829_CR32","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1097\/IAE.0000000000003699","volume":"43","author":"D Eichenbaum","year":"2023","unstructured":"Eichenbaum D, Brown DM, Ip M, Khanani AM, Figueroa MS, McAllister IL, et al. Impact of retinal fluid-free months on outcomes in neovascular age-related macular degeneration: a treatment agnostic analysis of the HAWK and HARRIER studies. Retina. 2023;43(4):632\u201340.","journal-title":"Retina."},{"key":"3829_CR33","unstructured":"Iyer PG, Shah CP. CST changes and VA in nAMD: a review of the evidence. 2023. https:\/\/www.retina-specialist.com\/article\/cst-changes-and-va-in-namd-a-reviewof-the-evidence."},{"issue":"1","key":"3829_CR34","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1001\/jamaophthalmol.2020.5044","volume":"139","author":"DJ Fu","year":"2021","unstructured":"Fu DJ, Keenan TD, Faes L, Lim E, Wagner SK, Moraes G, et al. Insights from survival analyses during 12 years of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration. JAMA Ophthalmol. 2021;139(1):57\u201367.","journal-title":"JAMA Ophthalmol"},{"issue":"12","key":"3829_CR35","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1001\/jamaophthalmol.2020.3989","volume":"138","author":"RP Finger","year":"2020","unstructured":"Finger RP, Puth MT, Schmid M, Barthelmes D, Guymer RH, Gillies M. Lifetime Outcomes of Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration. JAMA Ophthalmol. 2020;138(12):1234\u201340.","journal-title":"JAMA Ophthalmol"},{"key":"3829_CR36","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.2147\/OPTH.S242547","volume":"14","author":"AM Leys","year":"2020","unstructured":"Leys AM. Long-term ranibizumab treatment in neovascular age-related macular degeneration: a Belgian subanalysis from the global real-world LUMINOUS study. Clin Ophthalmol. 2020;14:1473\u201381.","journal-title":"Clin Ophthalmol"},{"key":"3829_CR37","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.2147\/OPTH.S218378","volume":"13","author":"F Horner","year":"2019","unstructured":"Horner F, Lip PL, Clark H, Chavan R, Sarmad A, Mushtaq B. Real-world visual and clinical outcomes for patients with neovascular age-related macular degeneration treated with intravitreal ranibizumab: an 8-year observational cohort (AMD8). Clin Ophthalmol. 2019;13:2461\u20137.","journal-title":"Clin Ophthalmol"},{"issue":"3","key":"3829_CR38","doi-asserted-by":"publisher","first-page":"210","DOI":"10.7326\/0003-4819-127-3-199708010-00006","volume":"127","author":"DJ Cook","year":"1997","unstructured":"Cook DJ, Greengold NL, Ellrodt AG, Weingarten SR. The relation between systematic reviews and practice guidelines. Ann Intern Med. 1997;127(3):210\u20136.","journal-title":"Ann Intern Med"},{"key":"3829_CR39","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.2147\/OPTH.S185052","volume":"12","author":"KL Spooner","year":"2018","unstructured":"Spooner KL, Mhlanga CT, Hong TH, Broadhead GK, Chang AA. The burden of neovascular age-related macular degeneration: a patient\u2019s perspective. Clin Ophthalmol. 2018;12:2483\u201391.","journal-title":"Clin Ophthalmol"},{"key":"3829_CR40","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1001\/jamaophthalmol.2021.1660","volume":"139","author":"M Okada","year":"2021","unstructured":"Okada M, Wong TY, Mitchell P, Finger RP, Eldem B, Talks SJ, Hirst C, et al. Defining nonadherence and nonpersistence to anti-vascular endothelial growth factor therapies in neovascular age-related macular degeneration [published correction appears in JAMA Ophthalmol. JAMA Ophthalmol. 2021;139:769\u201376.","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"3829_CR41","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/ANS.0000000000000263","volume":"42","author":"M Beauchemin","year":"2019","unstructured":"Beauchemin M, Cohn E, Shelton RC. Implementation of clinical practice guidelines in the health care setting: a concept analysis. ANS Adv Nurs Sci. 2019;42(4):307\u201324.","journal-title":"ANS Adv Nurs Sci"},{"key":"3829_CR42","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ajo.2017.03.005","volume":"177","author":"H Senra","year":"2017","unstructured":"Senra H, Balaskas K, Mahmoodi N, Aslam T. Experience of Anti-VEGF Treatment and Clinical Levels of Depression and Anxiety in Patients With Wet Age-Related Macular Degeneration. Am J Ophthalmol. 2017;177:213\u201324.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"3829_CR43","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1159\/000540390","volume":"67","author":"F Viola","year":"2024","unstructured":"Viola F, Chi GC, Holekamp NM, Giocanti-Auregan A, Garcia-Layana A, Peto T, et al. Caregiver experience survey of anti-vascular endothelial growth factor treatment for diabetic macular edema and neovascular age-related macular degeneration. Ophthalmic Res. 2024;67(1):516\u201327.","journal-title":"Ophthalmic Res"},{"issue":"2","key":"3829_CR44","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ophtha.2020.07.060","volume":"128","author":"M Okada","year":"2021","unstructured":"Okada M, Mitchell P, Finger RP, Eldem B, Talks SJ, Hirst C, et al. Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration: a mixed-methods systematic review. Ophthalmology. 2021;128(2):234\u201347.","journal-title":"Ophthalmology."},{"issue":"7","key":"3829_CR45","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1001\/archopht.119.7.1050","volume":"119","author":"CM Mangione","year":"2001","unstructured":"Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD, et al. Development of the 25-list-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2001;119(7):1050\u20138.","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"3829_CR46","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s40266-022-00937-y","volume":"39","author":"PS Calles-Monar","year":"2022","unstructured":"Calles-Monar PS, Sanabria MR, Alonso-Tarancon AM, Coco-Martin RM, Mayo-Iscar A. Modifiable determinants of satisfaction with intravitreal treatment in patients with neovascular age-related macular degeneration. Drugs Aging. 2022;39(5):355\u201366.","journal-title":"Drugs Aging"},{"issue":"8","key":"3829_CR47","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1001\/jamaophthalmol.2022.1091","volume":"140","author":"MA Chang","year":"2022","unstructured":"Chang MA, Kapre A, Kaufman D, Kardatzke DR, Rabena M, Patel S, et al. Patient preference and treatment satisfaction with a Port Delivery System for ranibizumab vs intravitreal injections in patients with neovascular age-related macular degeneration: a randomized clinical trial. JAMA Ophthalmol. 2022;140(8):771\u20138.","journal-title":"JAMA Ophthalmol"},{"key":"3829_CR48","doi-asserted-by":"crossref","unstructured":"Creuzot-Garcher CP, Srour M, Baudin F, Daien V, Dot C, Nghiem-Buffetet S, et al. Incidence and prevalence of neovascular age-related macular degeneration in France between 2008 and 2018: the LANDSCAPE study. Ophthalmol Sci. 2022;2(1):100114.","DOI":"10.1016\/j.xops.2022.100114"},{"key":"3829_CR49","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/s41598-020-58346-3","volume":"10","author":"Y Gao","year":"2020","unstructured":"Gao Y, Teo YCK, Beuerman RW, Wong TY, Zhou L, Cheung CMG. A serum metabolomics study of patients with nAMD in response to anti-VEGF therapy. Sci Rep. 2020;10:1341\u20132467. https:\/\/doi.org\/10.1038\/s41598-020-58346-3. Published 2020 Jan 28.","journal-title":"Sci Rep."},{"issue":"1","key":"3829_CR50","doi-asserted-by":"publisher","first-page":"e062158","DOI":"10.1136\/bmjopen-2022-062158","volume":"13","author":"T Wang","year":"2023","unstructured":"Wang T, Tan JB, Liu XL, Zhao I. Barriers and enablers to implementing clinical practice guidelines in primary care: an overview of systematic reviews. BMJ Open. 2023;13(1):e062158\u20132743.","journal-title":"BMJ Open"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03829-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03829-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03829-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T14:51:53Z","timestamp":1757170313000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03829-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":50,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["3829"],"URL":"https:\/\/doi.org\/10.1038\/s41433-025-03829-8","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,15]]},"assertion":[{"value":"18 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors made the following disclosures: J.I.L.: Consultant\/Advisor \u2013 AbbVie\/Allergan, Alimera, Astellas\/Iveric Bio, Aura, Cognition, Eyenuk, EyePoint, Genentech\/Roche, Luxa, Novartis, Regeneron, Unity, Viridian; Grant Support \u2013 Adverum, Aldeyra, BioSpring Vision, Genentech, Inc., Graybug, Janssen, Kyoto Drug Development, NGM Bio, Regeneron, Regenex, Stealth; Honoraria: Bausch + Lomb, Iveric Bio; S.K.: Employee \u2013 Genentech, Inc.; K.B.: Employee \u2013 Genentech, Inc.; E.M.: Employee \u2013 Genentech, Inc.; S.P.: Employee \u2013 Genentech, Inc.; G.S.: Employee \u2013 Genentech, Inc.; D.T.: Employee \u2013 Genentech, Inc. The other authors have no proprietary or commercial interest in any materials discussed in this article.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}